Which has higher valuation and earnings, ODD or NAGE?

ODDITY Tech has higher revenue and earnings than Niagen Bioscience. ODDITY Tech is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ODDITY Tech $809.84M 0.93 $110.75M $0.79 16.59 Niagen Bioscience $129.42M 1.86 $17.38M $0.18 16.78

Does the media favor ODD or NAGE?

In the previous week, Niagen Bioscience had 3 more articles in the media than ODDITY Tech. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for ODDITY Tech. ODDITY Tech's average media sentiment score of 1.20 beat Niagen Bioscience's score of -0.20 indicating that ODDITY Tech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ODDITY Tech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NAGE or BWMX?

Niagen Bioscience presently has a consensus price target of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Betterware de Mexico SAPI de C 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Does the media favor NAGE or BWMX?

In the previous week, Betterware de Mexico SAPI de C had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 10 mentions for Betterware de Mexico SAPI de C and 5 mentions for Niagen Bioscience. Betterware de Mexico SAPI de C's average media sentiment score of 0.97 beat Niagen Bioscience's score of -0.20 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Betterware de Mexico SAPI de C 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HNST or NAGE?

In the previous week, Honest had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 18 mentions for Honest and 5 mentions for Niagen Bioscience. Honest's average media sentiment score of 0.89 beat Niagen Bioscience's score of -0.20 indicating that Honest is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Honest 9 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NATR or NAGE?

In the previous week, Nature's Sunshine Products had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 10 mentions for Nature's Sunshine Products and 5 mentions for Niagen Bioscience. Nature's Sunshine Products' average media sentiment score of 1.69 beat Niagen Bioscience's score of -0.20 indicating that Nature's Sunshine Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nature's Sunshine Products 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NAGE or YSG?

Niagen Bioscience presently has a consensus target price of $10.33, suggesting a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Niagen Bioscience is more favorable than Yatsen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Yatsen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Niagen Bioscience (NAGE) Competitors

$3.02 -0.03 (-0.98%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.04 +0.02 (+0.83%)

As of 08/14/2026 07:42 PM Eastern

Compare

NAGE vs. ODD, BWMX, HNST, NATR, and YSG

Should you buy Niagen Bioscience stock or one of its competitors? Niagen Bioscience's main competitors and comparable companies include ODDITY Tech (ODD), Betterware de Mexico SAPI de C (BWMX), Honest (HNST), Nature's Sunshine Products (NATR), and Yatsen (YSG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Niagen Bioscience compare to ODDITY Tech?

ODDITY Tech (NASDAQ:ODD) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

ODDITY Tech has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market.

In the previous week, Niagen Bioscience had 3 more articles in the media than ODDITY Tech. MarketBeat recorded 5 mentions for Niagen Bioscience and 2 mentions for ODDITY Tech. ODDITY Tech's average media sentiment score of 1.20 beat Niagen Bioscience's score of -0.20 indicating that ODDITY Tech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ODDITY Tech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.9% of ODDITY Tech shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Niagen Bioscience has a net margin of 12.39% compared to ODDITY Tech's net margin of 6.97%. Niagen Bioscience's return on equity of 17.95% beat ODDITY Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ODDITY Tech	6.97%	15.38%	4.99%
Niagen Bioscience	12.39%	17.95%	13.17%

ODDITY Tech currently has a consensus target price of $25.39, indicating a potential upside of 93.64%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than ODDITY Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ODDITY Tech	4 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.69
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

ODDITY Tech has higher revenue and earnings than Niagen Bioscience. ODDITY Tech is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ODDITY Tech	$809.84M	0.93	$110.75M	$0.79	16.59
Niagen Bioscience	$129.42M	1.86	$17.38M	$0.18	16.78

Summary

Niagen Bioscience beats ODDITY Tech on 11 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Niagen Bioscience (NASDAQ:NAGE) and Betterware de Mexico SAPI de C (NYSE:BWMX) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.86	$17.38M	$0.18	16.78
Betterware de Mexico SAPI de C	$744M	0.82	$55.37M	$1.83	8.99

Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Betterware de Mexico SAPI de C has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to Betterware de Mexico SAPI de C's net margin of 8.35%. Betterware de Mexico SAPI de C's return on equity of 77.89% beat Niagen Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Betterware de Mexico SAPI de C	8.35%	77.89%	11.28%

Niagen Bioscience presently has a consensus price target of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Betterware de Mexico SAPI de C	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Betterware de Mexico SAPI de C had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 10 mentions for Betterware de Mexico SAPI de C and 5 mentions for Niagen Bioscience. Betterware de Mexico SAPI de C's average media sentiment score of 0.97 beat Niagen Bioscience's score of -0.20 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Betterware de Mexico SAPI de C	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 12.7% of Betterware de Mexico SAPI de C shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 10 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Honest?

Honest (NASDAQ:HNST) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, Honest had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 18 mentions for Honest and 5 mentions for Niagen Bioscience. Honest's average media sentiment score of 0.89 beat Niagen Bioscience's score of -0.20 indicating that Honest is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Honest	9 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

45.5% of Honest shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Honest shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Niagen Bioscience has lower revenue, but higher earnings than Honest. Honest is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Honest	$371.32M	1.43	-$15.69M	-$0.11	N/A
Niagen Bioscience	$129.42M	1.86	$17.38M	$0.18	16.78

Honest has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

Honest presently has a consensus target price of $4.84, indicating a potential upside of 0.00%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Honest.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Honest	2 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.22
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Niagen Bioscience has a net margin of 12.39% compared to Honest's net margin of -3.56%. Niagen Bioscience's return on equity of 17.95% beat Honest's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Honest	-3.56%	4.31%	3.33%
Niagen Bioscience	12.39%	17.95%	13.17%

Summary

Niagen Bioscience beats Honest on 11 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Nature's Sunshine Products?

Nature's Sunshine Products (NASDAQ:NATR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Niagen Bioscience has a net margin of 12.39% compared to Nature's Sunshine Products' net margin of 3.68%. Niagen Bioscience's return on equity of 17.95% beat Nature's Sunshine Products' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nature's Sunshine Products	3.68%	12.88%	8.17%
Niagen Bioscience	12.39%	17.95%	13.17%

Nature's Sunshine Products presently has a consensus target price of $30.50, indicating a potential upside of 101.72%. Niagen Bioscience has a consensus target price of $10.33, indicating a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Niagen Bioscience is more favorable than Nature's Sunshine Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nature's Sunshine Products	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Nature's Sunshine Products has higher revenue and earnings than Niagen Bioscience. Nature's Sunshine Products is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nature's Sunshine Products	$480.14M	0.55	$19.52M	$1.01	14.97
Niagen Bioscience	$129.42M	1.86	$17.38M	$0.18	16.78

79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 3.1% of Nature's Sunshine Products shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nature's Sunshine Products has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

In the previous week, Nature's Sunshine Products had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 10 mentions for Nature's Sunshine Products and 5 mentions for Niagen Bioscience. Nature's Sunshine Products' average media sentiment score of 1.69 beat Niagen Bioscience's score of -0.20 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nature's Sunshine Products	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Niagen Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Niagen Bioscience beats Nature's Sunshine Products on 11 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Yatsen?

Niagen Bioscience (NASDAQ:NAGE) and Yatsen (NYSE:YSG) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Niagen Bioscience has higher earnings, but lower revenue than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.86	$17.38M	$0.18	16.78
Yatsen	$614.62M	0.52	-$11.56M	-$0.21	N/A

Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, Yatsen has a beta of -1.55, indicating that its stock price is 255% less volatile than the broader market.

15.4% of Niagen Bioscience shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 29.0% of Yatsen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience has a net margin of 12.39% compared to Yatsen's net margin of -3.04%. Niagen Bioscience's return on equity of 17.95% beat Yatsen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Yatsen	-3.04%	-4.54%	-3.49%

Niagen Bioscience presently has a consensus target price of $10.33, suggesting a potential upside of 242.16%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Niagen Bioscience is more favorable than Yatsen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Yatsen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Niagen Bioscience had 5 more articles in the media than Yatsen. MarketBeat recorded 5 mentions for Niagen Bioscience and 0 mentions for Yatsen. Yatsen's average media sentiment score of 0.00 beat Niagen Bioscience's score of -0.20 indicating that Yatsen is being referred to more favorably in the news media.

Company	Overall Sentiment
Niagen Bioscience	Neutral
Yatsen	Neutral

Summary

Niagen Bioscience beats Yatsen on 14 of the 17 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$242.91M	$22.60B	$16.13B	$13.10B
Dividend Yield	N/A	4.29%	3.20%	10.45%
P/E Ratio	16.78	15.46	13.33	25.28
Price / Sales	1.86	12.56	262,280.37	91.83
Price / Cash	15.04	29.73	57.60	50.90
Price / Book	2.90	2.80	5.06	6.24
Net Income	$17.38M	$1.08B	$831.83M	$347.60M
7 Day Performance	-3.21%	-0.93%	0.58%	1.06%
1 Month Performance	-12.97%	-0.42%	1.48%	0.81%
1 Year Performance	-69.86%	-13.80%	13.68%	20.90%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	3.7387 of 5 stars	$3.02 -1.0%	$10.33 +242.2%	-68.9%	$242.91M	$129.42M	16.78	120
ODD ODDITY Tech	3.7813 of 5 stars	$13.65 -10.3%	$25.39 +86.0%	-77.5%	$785.50M	$739.71M	17.27	342	Positive News
BWMX Betterware de Mexico SAPI de C	4.1228 of 5 stars	$16.79 -2.4%	N/A	+27.3%	$628.47M	$744M	9.20	2,441
HNST Honest	2.0839 of 5 stars	$5.45 +41.6%	$4.18 -23.3%	+22.8%	$598.39M	$352.17M	N/A	190	Analyst Upgrade Insider Trade High Trading Volume
NATR Nature's Sunshine Products	4.2265 of 5 stars	$20.18 +0.6%	$34.50 +71.0%	-8.8%	$354.76M	$480.14M	18.35	850	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. ODD, BWMX, HNST, NATR, and YSG

How does Niagen Bioscience compare to ODDITY Tech?

Summary

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Summary

How does Niagen Bioscience compare to Honest?

Summary

How does Niagen Bioscience compare to Nature's Sunshine Products?

Summary

How does Niagen Bioscience compare to Yatsen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. ODD, BWMX, HNST, NATR, and YSG

How does Niagen Bioscience compare to ODDITY Tech?

Which has more volatility and risk, ODD or NAGE?

Does the media favor ODD or NAGE?

Do insiders and institutionals believe in ODD or NAGE?

Is ODD or NAGE more profitable?

Do analysts rate ODD or NAGE?

Which has higher valuation and earnings, ODD or NAGE?

Summary

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Which has higher valuation & earnings, NAGE or BWMX?

Which has more risk & volatility, NAGE or BWMX?

Is NAGE or BWMX more profitable?

Do analysts prefer NAGE or BWMX?

Does the media favor NAGE or BWMX?

Do institutionals and insiders believe in NAGE or BWMX?

Summary

How does Niagen Bioscience compare to Honest?

Does the media refer more to HNST or NAGE?

Do institutionals & insiders have more ownership in HNST or NAGE?

Which has higher valuation and earnings, HNST or NAGE?

Which has more volatility & risk, HNST or NAGE?

Do analysts recommend HNST or NAGE?

Is HNST or NAGE more profitable?

Summary

How does Niagen Bioscience compare to Nature's Sunshine Products?

Is NATR or NAGE more profitable?

Do analysts prefer NATR or NAGE?

Which has preferable earnings & valuation, NATR or NAGE?

Do insiders and institutionals believe in NATR or NAGE?

Which has more volatility and risk, NATR or NAGE?

Does the media favor NATR or NAGE?

Summary

How does Niagen Bioscience compare to Yatsen?

Which has preferable valuation & earnings, NAGE or YSG?

Which has more volatility and risk, NAGE or YSG?

Do institutionals and insiders hold more shares of NAGE or YSG?

Is NAGE or YSG more profitable?

Do analysts recommend NAGE or YSG?

Does the media favor NAGE or YSG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools